Enhanced TGFα-EGFR expression and P53 gene alterations contributes to gastric tumors aggressiveness

Cancer Letters

Volumn 212, Issue 1, 2004, Pages 33-41

  Espinoza, Luis A ^a,c   Tone, Luiz Gonzaga ^a   Neto, José Barbieri ^a   Costa, Roberto Silva ^a   Wang, Qiming J ^b   Ballejo, Gustavo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EGFR; Gastric adenocarcinomas; p16INK4; p21WAF1 CIP1; p53; TGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P16; PROTEIN P21; PROTEIN P53; TRANSFORMING GROWTH FACTOR ALPHA; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; PROTEIN P16INK4A;

ADULT; ADVANCED CANCER; ARTICLE; CANCER INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; EARLY CANCER; EXON; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; P53 GENE; PARAMETER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAMPLE; SINGLE STRAND CONFORMATION POLYMORPHISM; STOMACH ADENOCARCINOMA; STOMACH TUMOR; ADENOCARCINOMA; BIOSYNTHESIS; GENETICS; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA MUTATIONAL ANALYSIS; ENZYME INHIBITORS; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 3042773019     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.03.037     Document Type: Article

References (36)

1. Werner M., Becker K.F., Keller G., Hofler H. Gastric adenocarcinoma: pathomorphology and molecular pathology. J Cancer Res. Clin. Oncol. 127:2001;207-216
2. Garcia I., Vizoso F., Martin A., Sanz L., Abdel-Lah O., Raigoso P., Garcia-Muniz J.L. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann. Surg. Oncol. 10:2003;234-241
3. Holbro T., Civenni G., Hynes N.E. The ErbB receptors and their role in cancer progression. Exp. Cell. Res. 284:2003;99-110
4. Cascinu S., Graziano F., Delferro E., Staccioli M.P., Ligi M., Carnevali A., et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer. 83:1998;1917-1922
5. Hurlimann J., Saraga E.P. Expression of p53 protein in gastric carcinomas. Am. J. Surg. Pathol. 18:1994;1247-1253
6. Martin H.M., Filipe M.I., Morris R.W., Lane D.P., Silvestre F. p53 expression and prognosis in gastric carcinoma. Int. J. Cancer. 50:1992;859-862
7. Gomyo Y., Ikeda M., Osaki M., Tatebe S., Tsujitani S., Ikeguchi M., et al. Expression of p21 (waf1/cip1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer. 79:1997;2067-2072
8. Noda H., Maehara Y., Irie K., Kakeji Y., Yonemura T., Sugimachi K. Increased proliferative activity caused by loss of p21(WAF1/CIP1) expression and its clinical significance in patients with early-stage gastric carcinoma. Cancer. 94:2002;2107-2112
9. Okada Y., Hurwitz E.E., Esposito J.M., Brower M.A., Nutt C.L., Louis D.N. Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer Res. 63:2003;413-416
10. Grandis J.R., Zeng Q., Drenning S.D., Tweardy D.J. Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line. Int. J. Oncol. 13:1998;375-378
11. UICC. Sobin L.H., Wittekind C. TNM Classification of Malignant Tumor. 5th ed :1997;Wiley, New York
12. Lauren P. The two histological main types of gastric carcinomas: diffuse and socalled intestine-type carcinoma. Acta Pathol. Imicrobiol. Immunol. Scand. 64:1965;31-49
13. Ishida K., Katsuyama T., Sugiyama A., Kawasaki S. Immunohistochemical evaluation of lymph node micrometastases from gastric carcinomas. Cancer. 79:1997;1069-1076
14. Koyama S., Ikeda K., Sato M., Shibahara K., Yuhara K., Fukutomi H., et al. Transforming growth factor-alpha (TGF()-producing gastric carcinoma with acanthosis nigricans: An endocrine effect of TGF-( in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus. J Gastroenterol. 32:1997;71-77
15. c-erbB-2. Oncology. 52:1995;385-391
16. Yonemura Y., Takamura H., Ninomiya I., Fushida S., Tsugawa K., Kaji M., et al. Interrelationship between transforming growth factor-alpha and epidermal growth factor receptor in advanced gastric cancer. Oncology. 49:1992;157-161
17. Karameris A., Kanavaros P., Aninos D., Gorgoulis V., Mikou G., Rokas T., et al. Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases. Pathol. Res. Pract. 189:1993;133-137
18. Kopp R., Ruge M., Rothbauer E., Cramer C., Kraemling H.J., Wiebeck B., et al. Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res. 22:2002;1161-1167
19. Masaki T., Hatanaka Y., Nishioka M., Tokuda M., Shiratori Y., Reginfo W., Omata M. Activation of epidermal growth factor receptor kinase in gastric carcinoma: a preliminary study. Am. J. Gastroenterol. 95:2000;2135-2136
20. Shimada S., Yagi Y., Honmyo U., Shiomori K., Yoshida N., Ogawa M. Involvement of three or more lymph nodes predicts poor prognosis in submucosal gastric carcinoma. Gastric Cancer. 4:2001;54-59
21. Baldus S.E., Schneider P.M., Monig S.P., Zirbes T.K., Fromm S., Meyer W., et al. p21/waf1/cip1 in gastric cancer: associations with histopathological subtypes, lymphonodal metastasis, prognosis and p53 status. Scand. J. Gastroenterol. 36:2001;975-980
22. Ikeguchi M., Saito H., Kondo A., Tsujitani S., Maeta M., Kaibara N. Mutated p53 protein expression and proliferative activity in advanced gastric cancer. Hepatogastroenterology. 46:1999;2648-2653
23. Kakeji Y., Korenaga D., Tsujitani H., Baba H., Anai H., Maehara Y., Ugimachi K. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br. J. Cancer. 67:1993;589-593
24. Kim J.-H., Uhm H.D., Gong S.J., Shin D.H., Choi J.H., Lee R.H., et al. Relationship between p53 overexpression and gastric cancer progression. Oncology. 54:1997;166-170
25. Joypaul B.V., Newman E.L., Hopwood D., Grant A., Qureshi S., Lane D.P., Cushieri A. Expression of p53 protein normal dysplastic and malignant gastric mucosa: An immunohistochemical study. J. Pathol. 170:1993;279-283
26. Simmons M.L., Lamborn K.R., Takahashi M., Chen P., Israel M.A., Berger M.S., et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastomapatients. Cancer Res. 61:2001;1122-1128
27. Espinoza L., Barbieri Neto J., Casartelli C. Pathological and karyotypic abnormalities in advanced gastric carcinomas. Cancer Genet. Cytogenet. 109:1999;45-50
28. Kim Y.H., Kim N.G., Lim J.G., Park C., Kim H. Chromosomal alterations in paired gastric adenomas and carcinomas. Am. J. Pathol. 158:2001;655-662
29. Abe T., Terada K., Wakimoto H., Inoue R., Tyminski E., Bookstein R., et al. PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res. 63:2003;2300-2305
30. Yasui W., Akama Y., Hiroki K., Yokozaki H., Semba S., Shimamoto F., Tahara E. Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: Relationship with p53 status and proliferative activity. J. Pathol. 180:1996;122-128
31. Philipp-Staheli J., Kim K.-H., Liggit D., Gurley K.E., Longton G., Kemp C.J. Distinct roles for p53, p27Kip1, and p21WAF1/CIP1 during tumor development. Oncogene. 23:2004;905-913
32. Steinman H.A., Sluss H.K., Sands A.T., Pihan G., Jones S.N. Absence of p21 partially rescues Mdm4 loss and uncovers an antiproliferative effect of Mdm4 on cell growth. Oncogene. 23:2004;303-306
33. Myung N., Kim M.R., Chung I.P., Kim H., Jang J.J. Loss of p16 and p27 is associated with progression of human gastric cancer. Cancer Let. 153:2000;129-136
34. Rocco A., Schandl L., Nardone G., Tulassay Z., Staibano S., Malfertheiner P., Ebert M.P. Loss of expression of tumor suppressor p16(INK4) protein in human primary gastric cancer is related to the grade of differentiation. Dig. Dis. 20:2002;102-105
35. Tsujie M., Yamamoto H., Tomita N., Sugita Y., Ohue M., Sakita I., et al. Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer. Oncology. 58:2000;126-136
36. Lee W.A., Woo D.-K., Kim Y.I., Kim W.H. P53, p16 and Rb expression in adenosquamous and squamous cell carcinomas of the stomach. Pathol. Res. Pract. 195:1999;747-752